产品
  • 产品
  • 供应商
  • 采购
  • 资讯
  • 会展
首页 制药产品大全 原料药 甘精胰岛素 / Insuli...

甘精胰岛素 / Insulin Glargine

2025-06-18
160337-95-1
中国药典,美国药典,欧洲药典
注射级

产品详情
下载产品资料

甘精胰岛素 / Insulin Glargine
其他西药原料
160337-95-1
中国药典,美国药典,欧洲药典
注射级
甘精胰岛素,Insulin Glargine
中国,北美洲,中/南美洲,西欧,东欧,大洋洲,亚洲,中东,非洲

产品描述

甘精胰岛素是一种长效人胰岛素类似物,A链和B链经修饰后在酸性条件下比普通胰岛素更稳定,作用时间可持续24小时。甘精胰岛素用于治疗糖尿病,可与胰岛素受体(IR)结合,以模仿内源性人胰岛素的活性,促进葡萄糖代谢。

本品由能高效表达甘精胰岛素的大肠杆菌菌株经发酵而来,纯度高,内毒素含量极低,且不含任何动物源性病原体。

Glargine is a long-acting human insulin analog, with modified A and B chains that are more stable than regular insulin under acidic conditions and have a duration of action of up to 24 h. Insulin Glargine is commonly used in the treatment of diabetes and binds to the insulin receptor (IR) to mimic the activity of endogenous human insulin and promote glucose metabolism.

Virtu Pharmako utilizes E. coli strains to produce insulin glargine. It has extremely low endotoxin content with high purity, and does not contain any animal-derived pathogens.

恒敬合创生物医药(浙江)有限公司
访问店铺
注册资本
公司地址
联系人

公司简介

恒敬生物根植于公司核心团队20多年的全球研发积累,创建国际领先的生物制药企业,自创成熟、高效、大规模、成本极具竞争力的生物医药产品,产品涵盖胰岛素类药物、GLP-1类药物以及更多的蛋白类、多肽类产品,位于嘉兴的先进工厂一期设计产能3吨原液和过亿支制剂,二期原液产能超10吨。Virtu Pharmako is a leading biopharmaceutical company with R&D, regulatory submission and CGMP manufacture engaged in four major business areas: Insulin drug portfolio, GLP-1 drug portfolio, biosynthetic technique corporations and varieties of protein/polypeptide bioproducts.With more than 20 years of global R&D study and commercial experiences, the company established the unique, innovative biotechnology platform which efficiently developed dozens of cost-competitive, environment friendly and commercial-scale biomedical products.Our state-of-art, world leading biopharmaceutical manufacture facility with building area 1 Million ft2 is built up in Jiaxing, Zhejiang, China, where located in near Metropolitan City, Shanghai. In Phase I, the production capacity includes 3 metric tonnes per year of API and over 120 million units per year of injectable. Production capacity of Phase II will surpasses 10 metric tonnes of API.
业务类型:
成立日期:
年营业额:
主营产品类别: